Eli Lilly and Company $LLY Holdings Lifted by Groupe la Francaise

Groupe la Francaise raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 143,142 shares of the company’s stock after buying an additional 10,966 shares during the quarter. Eli Lilly and Company comprises approximately 2.0% of Groupe la Francaise’s holdings, making the stock its 9th largest position. Groupe la Francaise’s holdings in Eli Lilly and Company were worth $171,293,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Coastal Bridge Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $2,959,000. Mosaic Family Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 70.6% in the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after acquiring an additional 1,430 shares during the last quarter. Generali Investments Management Co LLC grew its position in Eli Lilly and Company by 17.5% in the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock worth $12,258,000 after acquiring an additional 1,521 shares in the last quarter. Moran Wealth Management LLC grew its position in Eli Lilly and Company by 85.6% in the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock worth $25,072,000 after acquiring an additional 9,638 shares in the last quarter. Finally, Amundi increased its stake in Eli Lilly and Company by 9.9% during the first quarter. Amundi now owns 5,055,025 shares of the company’s stock worth $4,649,464,000 after acquiring an additional 454,549 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.0%

Shares of NYSE:LLY opened at $1,123.42 on Thursday. Eli Lilly and Company has a 1 year low of $712.05 and a 1 year high of $1,292.65. The business has a 50 day simple moving average of $1,187.24 and a two-hundred day simple moving average of $1,072.08. The firm has a market capitalization of $1.06 trillion, a PE ratio of 37.70, a price-to-earnings-growth ratio of 1.39 and a beta of 0.50. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter in the prior year, the firm posted $6.31 earnings per share. The company’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities analysts predict that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 23.22%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Wolfe Research restated an “outperform” rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Cantor Fitzgerald boosted their target price on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Wells Fargo & Company increased their price target on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Guggenheim raised their price target on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $1,419.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,292.18.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Mounjaro’s expanded cardiovascular use could extend growth. The FDA approved Mounjaro to reduce heart-attack and stroke risk in adults with type 2 diabetes, potentially broadening prescribing, reimbursement and the drug’s addressable market. Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?
• Positive Sentiment: Demand and the broader pipeline remain major bullish themes. Commentary says Lilly’s incretin revenue is helping finance investments in neuroscience and other potential long-term growth drivers. Prior decisions to ration or limit some launches indicate demand exceeded available supply, although capacity constraints also remain an execution risk. Eli Lilly’s pipeline in 2026: how the incretin boom is funding what comes next
• Positive Sentiment: Analysts remain constructive. Recent analyst coverage highlights strong demand, strategic expansion and attractive medium-term prospects from Lilly’s leadership in the GLP-1 market. These reports may help support the stock after its substantial year-long advance. Top Analyst Reports for Eli Lilly, Palo Alto Networks & Texas Instruments
• Neutral Sentiment: Legal and competitive developments are being monitored. Lilly continues legal action against a seller of weight-loss products, while Novo Nordisk’s positive pediatric semaglutide data underscores intense competition in obesity care. Eli Lilly lawsuit against weight-loss drug seller gets another shave
• Negative Sentiment: Weakness in the healthcare sector and a failed Novartis cholesterol trial pressured sentiment. Investors appear concerned that the setback could undermine confidence in the broader Lp(a) cholesterol-drug class, creating negative read-through for Lilly despite the company’s separate growth drivers. Eli Lilly Stock Falls on Competitor Novartis’ Cholesterol Drug Setback

Insiders Place Their Bets

In other news, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 over the last quarter. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.